Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.
BACKGROUND
Directly administered antiretroviral therapy (DAART) is one approach to improve treatment adherence among human immunodeficiency virus (HIV)-infected drug users.


METHODS
In this randomized, controlled trial (ClinicalTrials.gov identifier, NCT00367172), the biological outcomes of a 6-month community intervention of DAART were compared with those of self-administered therapy among HIV-infected drug users. Patients randomized to receive DAART received supervised therapy 5 days per week from workers in a mobile health care van. The primary outcome, using an intention-to-treat approach, was the proportion of patients achieving either a reduction in HIV-1 RNA level of > or = 1.0 log10 copies/mL or an HIV-1 RNA level < or = 400 copies/mL at 6 months. Secondary outcomes included the mean change from baseline in HIV-1 RNA level and CD4+ T lymphocyte count.


RESULTS
Of the 141 patients who met the entry criteria, 88 were randomized to receive DAART, and 53 were randomized to receive self-administered therapy; 74 (84%) of 88 of the patients randomized to receive DAART accepted the intervention. Of the 74 patients who initiated DAART, 51 (69%) completed the full 6-month intervention. At the end of 6 months, a significantly greater proportion of the DAART group achieved the primary outcome (70.5% vs. 54.7; P=.02). Additionally, compared with patients receiving self-administered therapy, patients receiving DAART demonstrated a significantly greater mean reduction in HIV-1 RNA level (-1.16 log10 copies/mL vs. -0.29 log10 copies/mL; P=.03) and mean increase in CD4+ T lymphocyte count (+58.8 cells/microL vs. -24.0 cells/microL; P=.002).


CONCLUSIONS
This randomized, controlled trial was, to our knowledge, the first to demonstrate the effectiveness of DAART at improving 6-month virologic outcomes among drug users. These results suggest that DAART should be more widely available in HIV treatment programs that target drug users who have poor adherence to treatment.
Altice
Frederick L
FL
Yale University AIDS Program, Yale University, New Haven, CT 06510-2283, USA. raltice@aol.com
Maru
Duncan Smith-Rohrberg
DS
Bruce
R Douglas
RD
Springer
Sandra A
SA
Friedland
Gerald H
GH
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D023801:Directly Observed Therapy / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data; D011446:Prospective Studies; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D012646:Self Administration / Q000379:methods; D019966:Substance-Related Disorders / Q000150:complications*; D016896:Treatment Outcome
D012367:RNA, Viral
Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S429-36
15156434
Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S409-13
15156431
JAMA. 2004 Jul 14;292(2):251-65
15249575
Br J Anaesth. 1980 Oct;52(10):1013-9
7437209
N Engl J Med. 1994 Apr 28;330(17):1179-84
8139628
JAMA. 1995 Sep 27;274(12):945-51
7674524
Clin Pharmacol Ther. 1997 Jan;61(1):70-82
9024175
Int J Epidemiol. 1997 Dec;26(6):1367-72
9447419
JAMA. 1998 Mar 25;279(12):943-8
9544769
JAMA. 1998 Aug 12;280(6):547-9
9707146
Ann Epidemiol. 1999 Feb;9(2):127-31
10037557
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):220-7
10077169
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):545-50
16044005
Am J Epidemiol. 2006 Mar 1;163(5):412-20
16394200
Clin Infect Dis. 2006 Jun 1;42(11):1619-27
16652320
Clin Infect Dis. 2006 Oct 1;43(7):939-41
16941380
J Infect Dis. 2006 Oct 15;194(8):1108-14
16991085
Clin Infect Dis. 2006 Nov 1;43(9):1221-2; author reply 1222-3
17029149
J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S41-7
17091022
J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S48-53
17133204
AIDS Behav. 2007 Mar;11(2):161-73
16804749
J Urban Health. 1999 Dec;76(4):468-80
10609596
J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):358-63
10634197
Med Care. 2000 Apr;38(4):404-10
10752972
Lancet. 2001 Apr 14;357(9263):1149-53
11323041
Am J Med. 2001 Jun 1;110(8):664-6
11382379
AIDS. 2001 Jun 15;15(9):1181-3
11416722
J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):251-9
11464144
AIDS. 2001 Sep 7;15(13):1707-15
11546947
Clin Infect Dis. 2001 Oct 15;33(8):1417-23
11550118
Control Clin Trials. 2001 Dec;22(6):639-58
11738121
Clin Infect Dis. 2002 Apr 1;34(7):984-90
11880965
AIDS. 2002 Mar 29;16(5):767-74
11964533
J Gen Intern Med. 2002 May;17(5):377-81
12047736
AIDS Patient Care STDS. 2002 Nov;16(11):527-35
12513901
Ann Intern Med. 2003 Apr 15;138(8):620-6
12693883
AIDS. 2003 Jun 13;17(9):1383-7
12799560
Clin Infect Dis. 2003 Jun 15;36(12):1572-6
12802758
Am J Med. 2003 Dec 1;115(8):632-41
14656616
Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):331-5
15024621
J Acquir Immune Defic Syndr. 2004 May 1;36(1):642-5
15097311
Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S376-87
15156426
Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S402-8
15156430
Lancet. 2004 Jul 3-9;364(9428):51-62
15234856